Healthcare provider profile · identity verified

Mark Braun, MD

Internal Medicine · SCARBOROUGH, ME · NPI 1851327936

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	290	77
Hydrochlorothiazide	Hydrochlorothiazide	219	62
Amlodipine Besylate	Amlodipine Besylate	210	52
Lisinopril	Lisinopril	165	45
Levothyroxine Sodium	Levothyroxine Sodium	133	33
Metformin Hcl	Metformin Hcl	126	33
Eliquis	Apixaban	91	18
Omeprazole	Omeprazole	87	26
Metoprolol Succinate	Metoprolol Succinate	85	26
Lorazepam	Lorazepam	84	17
Simvastatin	Simvastatin	81	22
Losartan Potassium	Losartan Potassium	80	21
Tamsulosin Hcl	Tamsulosin Hcl	66	18
Furosemide	Furosemide	65	22
Rosuvastatin Calcium	Rosuvastatin Calcium	65	17
Pravastatin Sodium	Pravastatin Sodium	58	15
Sertraline Hcl	Sertraline Hcl	58	16
Jardiance	Empagliflozin	45	suppressed
Alendronate Sodium	Alendronate Sodium	43	11
Gabapentin	Gabapentin	41	14
Labetalol Hcl	Labetalol Hcl	38	suppressed
Baclofen	Baclofen	36	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	30	suppressed
Finasteride	Finasteride	29	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	27	suppressed
Trazodone Hcl	Trazodone Hcl	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Irbesartan	Irbesartan	23	suppressed
Prednisone	Prednisone	23	12
Allopurinol	Allopurinol	21	suppressed
Atenolol	Atenolol	21	suppressed
Carvedilol	Carvedilol	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Nitroglycerin	Nitroglycerin	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Tresiba Flextouch U-100	Insulin Degludec	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Glipizide	Glipizide	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Nadolol	Nadolol	16	suppressed
Ozempic	Semaglutide	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Cephalexin	Cephalexin	15	12
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Methimazole	Methimazole	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Valsartan	Valsartan	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	12	suppressed
Estradiol	Estradiol	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Methylphenidate Er	Methylphenidate Hcl	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Zafirlukast	Zafirlukast	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error